Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by 2skytracker2on Mar 30, 2012 4:16pm

366 Views

Post# 19740871

.055

Nice finish for the week..........very encouraging..........might have more happening on mani# 1 next week.........lets keep our fingers crossed.

Foot note.......its nice to have all you fellow traders out there to bounce ideas off and your daily thoughts and comments (what ever they may be ) are appreciated!!!...... so thanks and have a great weekend.

ST

Bullboard Posts

Canadian psychedelic stock to supply MDMA to Yale